Evidence map›Paper›PMID 24952746›Full record

ArticleNature genetics2014

The genomic landscape of nasopharyngeal carcinoma.

De-Chen Lin, Xuan Meng, Masaharu Hazawa, Yasunobu Nagata, Ana Maria Varela, Liang Xu, Yusuke Sato, Li-Zhen Liu, Ling-Wen Ding, Arjun Sharma and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 1 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 1 synthesis or guideline pooled it, 373 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Novel Therapeutic Development for Nasopharyngeal Carcinoma.Current oncology (Toronto, Ont.) · 2025
    Review
  16. Article
  17. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  18. Article
  19. Article
  20. Article

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

De-Chen Lin1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, California, USA. [3].
Xuan Meng1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Medicine, School of Medicine, National University of Singapore, Singapore. [3].
Masaharu HazawaCancer Science Institute of Singapore, National University of Singapore, Singapore.
Yasunobu Nagata1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ana Maria VarelaCancer Science Institute of Singapore, National University of Singapore, Singapore.
Liang XuCancer Science Institute of Singapore, National University of Singapore, Singapore.
Yusuke Sato1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Li-Zhen LiuCancer Science Institute of Singapore, National University of Singapore, Singapore.
Ling-Wen DingCancer Science Institute of Singapore, National University of Singapore, Singapore.
Arjun SharmaCancer Science Institute of Singapore, National University of Singapore, Singapore.
Boon Cher Goh1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Haematology-Oncology, National University Cancer Institute, Singapore.
Soo Chin Lee1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Haematology-Oncology, National University Cancer Institute, Singapore.
Bengt Fredrik PeterssonDepartment of Pathology, National University Health System, Singapore.
Feng Gang YuDepartment of Otolaryngology, National University Hospital Singapore, Singapore.
Paul MacaryDepartment of Immunology, National University of Singapore, Singapore.
Min Zin OoDepartment of Immunology, National University of Singapore, Singapore.
Chan Soh HaDepartment of Microbiology, National University of Singapore, Singapore.
Henry Yang1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2].
Seishi Ogawa1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. [3].
Kwok Seng Loh1] Department of Otolaryngology, National University Hospital Singapore, Singapore. [2].
H Phillip Koeffler1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, California, USA. [3] National University Cancer Institute, National University Hospital Singapore, Singapore. [4].
National University of Singapore · SGNational University Cancer Institute, Singapore · SGThe University of Tokyo · JPNational University Hospital · SGCedars-Sinai Medical Center · USNational University Health System · SG

Funding

REGULATION OF HEMATOPOIETIC CYTOKINESR01CA026038 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOEFFLER, HAROLD PHILLIP · 1985 to 2013
$4.7M
NCI NIH HHS R01 CA026038NCI NIH HHS R01CA026038-35
6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) has extremely skewed ethnic and geographic distributions, is poorly understood at the genetic level and is in need of effective therapeutic approaches. Here we determined the mutational landscape of 128 cases with NPC using whole-exome and targeted deep sequencing, as well as SNP array analysis. These approaches revealed a distinct mutational signature and nine significantly mutated genes, many of which have not been implicated previously in NPC. Notably, integrated analysis showed enrichment of genetic lesions affecting several important cellular processes and pathways, including chromatin modification, ERBB-PI3K signaling and autophagy machinery. Further functional studies suggested the biological relevance of these lesions to the NPC malignant phenotype. In addition, we uncovered a number of new druggable candidates because of their genomic alterations. Together our study provides a molecular basis for a comprehensive understanding of, and exploring new therapies for, NPC.

Indexed as

AnimalsAutophagyCarcinomaCell LineCell Line, TumorErbB ReceptorsExomeGenomicsHEK293 CellsHeterograftsHumansMaleMice, Inbred NODMice, SCIDNasopharyngeal CarcinomaNasopharyngeal NeoplasmsEGFR protein, humanErbB ReceptorsPhosphatidylinositol 3-Kinases

Identifiers

PMID24952746
OpenAlexW2027671549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.